Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is well-positioned in the biotechnology industry with promising pipeline products, including two MTA-cooperative PRMT5 inhibitors targeting various cancer types. The company is already in partnerships with major players in the industry, and its innovative approach to precision medicine could lead to successful treatment options for patients. Financially, the company has a strong cash position and potential for revenue growth through partnerships and its own drugs in development. These factors make Tango Therapeutics a strong investment opportunity.

Bears say

Tango Therapeutics is heavily reliant on its PRMT5 inhibitors for both its pipeline and revenue potential, which makes it vulnerable to competition from both established and emerging players in the market. The company also faces significant financial challenges, with the need to raise capital through dilutive financing options, potentially leading to ownership dilution for investors. While the company has a head start in its PRMT5/ KRAS inhibitor combination therapy, if results do not meet expectations, it could result in significant downside risk for the stock.

Tango Therapeutics (TNGX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 11 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.